RSS Feed

Calendar

Search

Tag Cloud

Archives

Reuters (May 2)

2023/ 05/ 02 by jd in Global News

“Diversifying abroad looks attractive to many Japanese companies given weak home markets” as demonstrated by Astellas recent $5.9 billion acquisition of Iveric Bio. “For the $28 billion drugmaker, which already earns the bulk of its revenue from overseas, exceptionally low borrowing costs at home may have boosted its offshore appetite even more.”

 

[archive]